Assembly Biosciences, Inc. (ASMB): who owns it and who trades it
As of Nov 16, 2026, ASMB insiders reported 11 open-market sales worth $201K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason A Okazaki (CEO), with $122K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Assembly Biosciences
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ASMB
93 funds and institutions reported ASMB shares worth $516M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Gilead Sciences, Inc. with 31.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 4.98M | 31.38% | $137M | +10% |
| Farallon Capital Management, L.l.c. | 1.60M | 10.12% | $44.1M | +31% |
| Paradigm Biocapital Advisors LP | 1.55M | 9.79% | $42.7M | +134% |
| Commodore Capital LP | 1.42M | 8.92% | $38.9M | +42% |
| Ra Capital Management, L.P. | 1.02M | 6.43% | $28M | No change |
| Jupiter Topco LLC | 849,309 | 5.35% | $23.4M | New |
| BlackRock, Inc. | 766,819 | 4.83% | $21.1M | +278% |
| Parkman Healthcare Partners LLC | 721,181 | 4.55% | $19.8M | +75% |
| Vanguard Capital Management LLC | 558,942 | 3.52% | $15.4M | +14% |
| Point72 Asset Management, L.P. | 460,593 | 2.90% | $12.7M | +34% |
| Seven Fleet Capital Management LP | 433,147 | 2.73% | $11.9M | +671% |
| Millennium Management LLC | 298,807 | 1.88% | $8.2M | +28% |
| Geode Capital Management, LLC | 280,424 | 1.77% | $7.7M | +111% |
| Schonfeld Strategic Advisors LLC | 242,153 | 1.53% | $6.7M | +101% |
| Ameriprise Financial Inc | 230,000 | 1.45% | $6.3M | New |
| Dv Equities, LLC | 226,415 | 1.43% | $6.2M | New |
| Aberdeen Group plc | 207,047 | 1.31% | $5.7M | New |
| Affinity Asset Advisors, LLC | 190,000 | 1.20% | $5.2M | New |
| B Group, Inc. | 175,706 | 1.11% | $4.8M | No change |
| State Street Corp | 171,931 | 1.08% | $4.7M | +203% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ASMB insiders reported $0 of open-market purchases and $201K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Jason A Okazaki | CEO | Sale | 6,133 | $19.61 | $120K | Form 4 |
| Nov 2, 2026 | Jason A Okazaki | CEO | Sale | 69 | $20.35 | $1.4K | Form 4 |
| Nov 2, 2026 | Anuj Gaggar | Chief Medical Officer | Sale | 2,564 | $19.61 | $50.3K | Form 4 |
| Nov 2, 2026 | Anuj Gaggar | Chief Medical Officer | Sale | 29 | $20.35 | $590 | Form 4 |
| Nov 2, 2026 | Jeanette M Bjorkquist | PFO and PAO | Sale | 718 | $19.61 | $14.1K | Form 4 |
| Nov 2, 2026 | Jeanette M Bjorkquist | PFO and PAO | Sale | 9 | $20.35 | $183 | Form 4 |
| Jun 17, 2026 | Jeanette M Bjorkquist | PFO and PAO | Sale | 29 | $23.25 | $674 | Form 4 |
| Mar 30, 2026 | Jeanette M Bjorkquist | PFO and PAO | Sale | 16 | $27.49 | $440 | Form 4 |
| Mar 30, 2026 | Jeanette M Bjorkquist | PFO and PAO | Sale | 312 | $26.65 | $8.3K | Form 4 |
| Mar 30, 2026 | Nicole S White | Chief Manufacturing Offi | Sale | 9 | $27.49 | $247 | Form 4 |
| Mar 30, 2026 | Nicole S White | Chief Manufacturing Offi | Sale | 188 | $26.65 | $5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jason A Okazaki | CEO and President, Director | – | $122K | Nov 2, 2026 |
| Anuj Gaggar | Chief Medical Officer | – | $50.9K | Nov 2, 2026 |
| Jeanette M Bjorkquist | PFO and PAO | – | $23.7K | Nov 2, 2026 |
| Nicole S White | Chief Manufacturing Officer | – | $5.3K | Mar 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ASMB short interest
High short interest. 14.9% of ASMB shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 97%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.03M ASMB shares were sold short, 14.9% of the shares outstanding, up 4.1% from the report before. At the average daily volume of 178,424 shares, buying them all back would take about 17.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.03M | 14.89% | +4% | 178,424 | 17.0 |
| Oct 15, 2026 | 2.91M | 14.31% | +3% | 263,103 | 11.1 |
| Sep 30, 2026 | 2.82M | 13.86% | +35% | 412,950 | 6.8 |
| Sep 15, 2026 | 2.10M | 10.29% | -1% | 334,747 | 6.3 |
| Aug 31, 2026 | 2.12M | 10.41% | -8% | 314,272 | 6.8 |
| Aug 14, 2026 | 2.31M | 11.37% | -1% | 230,357 | 10.1 |
| Jul 31, 2026 | 2.34M | 14.73% | +1% | 147,661 | 15.8 |
| Jul 15, 2026 | 2.31M | 14.58% | -4% | 157,302 | 14.7 |
| Jun 30, 2026 | 2.41M | 15.18% | +29% | 365,563 | 6.6 |
| Jun 15, 2026 | 1.87M | 11.76% | +11% | 198,285 | 9.4 |
| May 29, 2026 | 1.68M | 10.62% | +9% | 223,737 | 7.5 |
| May 15, 2026 | 1.54M | 9.73% | -1% | 163,858 | 9.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Assembly Biosciences company events
Assembly Biosciences filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Aug 14, 2026.
- Aug 14, 2026ResultsAmended an earlier report. Released financial results. Filing
- Aug 13, 2026DealCompleted a purchase or sale of a business or assets. Filing
- Jun 5, 2026LeadershipAmendment No. 3 to Amended and Restated 2018 Stock Incentive Plan At the Assembly Biosciences, Inc. Annual Meeting of Stockholders held on June 4, 2026,, the Company's stockholders approved Amendment No. 3 to the Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan to increase… Filing
- May 26, 2026AgreementAssembly Biosciences, Inc. entered into an underwriting agreement with Guggenheim Securities, LLC and UBS Securities LLC, as representatives of the several underwriters listed in Schedule A thereto, in connection with the issuance and sale, in an underwritten, registered offering, of: (1) 3,358,602… Filing
- May 22, 2026AnnouncementThe Company has plans to expand the clinical development of 6250, its oral entry inhibitor candidate for chronic HDV infection, into PBC and PSC, broadening the program into cholestatic liver diseases. 6250 is currently being evaluated for chronic HDV infection and has completed a Phase 1a clinical… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 30, 2026LeadershipThe Compensation Committee of the Board of Directors of Assembly Biosciences, Inc. approved a new cash bonus plan, the 2026 Corporate Bonus Plan. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
- Dec 8, 2025AnnouncementABI-1179 The Company announced interim results from the 1179 Study. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Assembly Biosciences financials
Famous investors that hold ASMB
4 of the 50 well-known investors we track reported holding ASMB in their latest 13F filing. The largest position is Israel Englander's, worth $11.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 490,137 | $11.5M | 0.0% | +64% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 379,812 | $8.9M | 0.0% | +296% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 362,728 | $8.5M | 0.0% | -21% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 112,017 | $2.6M | 0.0% | +184% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ASMB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 3.3% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 3.3% |
Questions about Assembly Biosciences, Inc. (ASMB) stock
Who owns the most ASMB stock?
The largest reported owner of Assembly Biosciences, Inc. (ASMB) is Gilead Sciences, Inc., with 31.4% of the company. In total, 93 funds and institutions reported holding ASMB at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ASMB insiders buying or selling?
In the last 12 months, ASMB insiders reported no open-market purchases and 11 sales worth $201K. The latest trade was on Nov 2, 2026. See every trade.
What is the short interest in ASMB?
As of Oct 30, 2026, 3.03M ASMB shares were sold short, 14.9% of the shares outstanding, up 4.1% from the report before. At the average daily volume of 178,424 shares, buying them all back would take about 17.0 trading days (days to cover). See the history.
Which famous investors hold ASMB?
4 of the 50 well-known investors we track reported ASMB in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $11.5M. See all holders.
Executive pay
Assembly Biosciences's chief executive was paid a total of $2.5M for the year ended Dec 31, 2025, up 41% from $1.8M the year before. In the last 12 months, Assembly Biosciences's executives and directors bought no stock on the open market and sold $201K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.